Jun 08, 2023 / NTS GMT
Maury Raycroft - Jefferies - Analyst
Hi, Everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to welcome our guests Vince Anzalone, Head of IR; and James Hamilton, Chief Discovery and Translational Medicine of Arrowhead. This is going to be a fireside chat format. So maybe to start off, if you guys want to provide a brief intro to Arrowhead.
Vince Anzalone - Arrowhead Pharmaceuticals, Inc. - IR
Sure. Thanks, Mark, and thanks to the whole Jefferies team for having us today. So, Arrowhead is an RNAi therapeutics platform company. So, we have a proprietary technology platform called TRiM or targeted RNA molecules. It allows us to induce target gene silencing across multiple tissue types, including liver, lung, muscle, CNS, and emerging adipose. Right now, we have 12 clinical stage candidates, 7 of those are wholly owned, 5 are partnered. And we have a 20 in '25 initiative, where we want to grow our pipeline of both clinical stage and marketed products to 20 by the year 2025.
Arrowhead Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers